2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Apolipoprotein
  5. Apolipoprotein Isoform
  6. Apolipoprotein Inhibitor

Apolipoprotein Inhibitor

Apolipoprotein Inhibitors (5):

Cat. No. Product Name Effect Purity
  • HY-132820
    Inaxaplin
    		Inhibitor 98.78%
    Inaxaplin (VX-147) is an orally active apolipoprotein L1 (APOL1) function inhibitor (WO2020131807, compound 2). Inaxaplin can be used for the research of kidney disease.
  • HY-147425A
    Zerlasiran sodium
    		Inhibitor
    Zerlasiran sodium is an apolipoprotein A (ApoA) synthesis reducer.
  • HY-P99105
    Anselamimab
    		Inhibitor 98.96%
    Anselamimab (CAEL-101) a humanized IgG1-κ anti-Amyloid fibrils antibody targeting to serum amyloid A1 (SAA1).
  • HY-141885
    APOL1-IN-1
    		Inhibitor 99.62%
    APOL1-IN-1 is a apolipoprotein L1 (APOL1) inhibitor extracted from patent WO2020131807A1 compound 87. APOL1-IN-1 can be used for the research of focal segmental glomerulosclerosis (FSGS) and non-diabetic kidney disease (NDKD).
  • HY-147425
    Zerlasiran
    		Inhibitor
    Zerlasiran is an apolipoprotein A (ApoA) synthesis reducer.